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Malaria sporozoites induce swift activation of antigen-specific
CD8 T cells that inhibit the intracellular development of liver-
stage parasites. The length of time of functional in vivo antigen
presentation, estimated by monitoring the activation of antigen-
specific CD8 T cells, is of short duration, with maximum T cell
activation occurring within the first 8 h after immunization and
lasting approximately 48 h. Although the magnitude of the CD8
T cell response closely correlates with the number of parasites used
for immunization, increasing the time of antigen presentation by
daily immunizations does not enhance the magnitude of this
response. Thus, once a primary clonal burst is established, the
CD8 T cell response becomes refractory or unresponsive to
further antigenic stimulation. These findings strongly suggest that
the most efficient strategy for the induction of primary CD8 T cell
responses is the delivery of a maximal amount of antigen in a single
dose, thereby ensuring a clonal burst that involves the largest
number of precursors to become memory cells.
The CD8 T cells are the prime mediators of adaptiveimmunity against a number of intracellular parasites, bacte-
ria, and viruses. In rodent models of malaria parasite infection,
CD8 T cells induced after immunization with sporozoites play
a major role in protective immunity, inhibiting the development
of the liver stages of these parasites. Adoptive transfer of CD8
T cell clones specific for epitopes expressed in sporozoite and
liver stages strongly inhibits the intracellular development of
parasites (1–3). Moreover, CD8 T cells induced by immuni-
zation with subunit vaccines expressing these plasmodial anti-
gens can also abolish the intrahepatocytic development of these
parasites and prevent the occurrence of blood infections (4–8).
Studies in humans living in malaria-endemic areas indicate
that the CD8 T cell responses to liver stages are rather
restricted because they are usually found at very low levels, even
in individuals living in regions with intense malaria transmission
(9, 10). This phenomenon has been attributed to the existence of
altered peptide ligands resulting from polymorphisms present in
epitopes recognized by CD8 T cells, which could induce
antagonistic effects that may interfere with T cell priming and
the survival of memory cells (11, 12). The situation found in
human populations is not entirely different from that observed
in experimental rodent models. Immunization of mice with
Plasmodium yoelii sporozoites induces rather low CD8 T cell
responses, barely detectable by highly sensitive ex vivo assays
such as the enzyme immunospot assay (ELISPOT) (7, 13, 14).
The reduced magnitude of primary CD8 T cell responses
observed in normal mice does not appear to be caused by a low
immunogenicity of sporozoites. In fact, recent studies indicate
that immunization with malaria sporozoites induces a strong and
swift activation of naı¨ve CD8 T cell precursors. Using trans-
genic (Tg) mice bearing a T cell receptor specific for the
SYVPSAEQI epitope from the P. yoelii circumsporozoite pro-
tein, we demonstrated that within 24 h of immunization, naı¨ve
CD8 T cells already express effector functions, such as the
production of IFN and perforin and the capacity to eliminate
liver-stage parasites (15). Whereas the initiation of this T cell
differentiation and proliferation appears to be driven only by
antigen, IL-4-secreting CD4 T cells are crucial to sustain the
developing CD8 T cell response (16).
To identify and characterize the underlying mechanisms in-
fluencing the magnitude and efficiency of primary CD8 T cell
responses against malaria liver stages, we evaluated the role
played by antigen in the modulation and maintenance of these
responses. Although it is established that sporozoite immuniza-
tion induces the activation of antigen-specific CD8 T cells, it
is not known how long antigen presentation lasts and, more
important, how long this antigen presentation functions to
induce the activation of CD8 T cells. Here we report studies
aimed at estimating the duration of functional in vivo antigen
presentation after sporozoite immunization as determined by
measuring the activation of antigen-specific CD8 T cell pre-
cursors. We also investigated the effect of prolonged antigen
presentation and its effect on the magnitude of primary CD8
T cell responses. Understanding these issues should aid in the
design of vaccines not only against malaria but also for other
microbial diseases.
Materials and Methods
Mice and Parasites. Six- to eight-week-old female CB6F1 and
RAG2/ B10D2 mice were obtained from the National Cancer
Institute and The Jackson Laboratory, respectively. The gener-
ation of the SYVPSAEQI-specific T cell receptor Tg mice has
been described previously (15). P. yoelii 17XNL parasites were
maintained as described (2). Sporozoites were collected by
dissecting the salivary glands of infected Anopheles stephensi
mosquitoes 2 weeks after an infective blood meal.
Adoptive Transfer, Immunizations, and Drug Treatment. Spleen cells
from Tg mice (CB6F1 or B10D2 background) containing 1–2 
106 CD8 tetramer (see below) cells were injected i.v. into
syngenic mice. Reconstitution of RAG2/ B10D2 mice was
performed by i.v. transfer of60 106 spleen cells isolated from
normal syngenic mice in addition to the Tg cells. Immunizations
with sporozoites were performed by i.v. injection of 3–5  104
radiation-attenuated (-source, 20 krad) sporozoites or other-
wise specified in the figure legends. Infection via bites of
irradiated infected mosquitoes was performed as described (17,
18). To generate activatedmemory cells, mice that received Tg
cells were immunized i.v. with a recombinant vaccinia virus
(recVAC, 1  106 pfu per mouse) expressing the SYVPSAEQI
epitope (4, 19). Primaquine (Sigma) was administered s.c. (60
mgkg) as described (20).
H2Kd Tetramers, Cell Staining, and FACS Analysis. The SYVPSAEQI-
specific H2Kd tetramers were either obtained from the National
Institute of Allergy and Infectious Diseases, National Institutes
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of Health tetramer facility or prepared as described (21, 22).
Fluorescent-labeled mAb to mouse CD8 (53–6.7) were ob-
tained from PharMingen. Staining of cells for FACS analysis was
performed by using standard protocols after blocking with
unconjugated streptavidin (Molecular Probes) and FC block
(PharMingen). Cells were analyzed by using FACSCALIBUR and
CELL QUEST software (Becton Dickinson). Between 200,000 and
500,000 live events are usually acquired.
ELISPOT Assay and Cell Culture. The ex vivo IFN ELISPOT to
enumerate the number of SYVPSAEQI-specific CD8 T cells
was performed as described (14). MHC-compatible A20.2J
target cells were coated with the SYVPSAEQI peptide and were
incubated with mouse lymphocytes for 20–24 h. Anti-mouse
IFN (R4) and biotinylated anti-mouse IFN (XMG1.2) were
obtained from PharMingen.
Results
Short-Term Antigen Presentation Defines the Magnitude of the CD8
T Cell Response Against Malaria Liver Stages. In previous studies, by
using an adoptive transfer system with Tg CD8 T cells specific
for the SYVPSAEQI epitope of the P. yoelii circumsporozoite
protein, we determined that the activation of CD8 T cells and
the development of their antiparasitic functions are detectable as
early as 24 h after immunization. This T cell response reaches the
highest magnitude on day 4, suffers a major contraction between
days 6 and 7, and becomes stabilized after day 8 (15). After this
initial phase, the response remains unchanged in the spleen
and liver for at least 6 months (Fig. 1). These studies indicate
that a single immunization drives naı¨ve CD8 T cells to un-
dergo differentiation, proliferation, and later on, long-term
persistence.
These results raised the question regarding the length of time
of in vivo antigen presentation and the influence that it may have
on the generation and maintenance of CD8 T cell memory. In
studies with other microbial systems, this matter has been
investigated by using activatedmemory T cells obtained from
immunized mice that were transferred to naı¨ve mice to evaluate
the long-term maintenance of memory CD8 T cells in the
absence of antigen. This approach, however, has been criticized
as it cannot rule out the possibility that in addition to the CD8
T cells obtained from immunized mice, antigen or antigen-
bearing cells are also being transferred (23–29).
In view of this situation, and taking advantage of the specificity
and sensitivity of the Tg CD8 T cell system, we developed an
approach to estimate the duration of in vivo antigen presenta-
tion. In this system, mice were injected with attenuated sporo-
zoites, and at different time points after immunization, they
received naı¨ve Tg CD8 T cells. Four days after the transfer of
T cells into immunized mice, we evaluated the number as well as
the differentiation status of the CD8 T cells in the spleen and
liver by using ELISPOT and flow cytometry with SYVPSAEQI
tetramers. We found that in the spleen, maximum numbers of
SYVPSAEQI-specific IFN-secreting CD8 T cells were ob-
served when the Tg CD8 cells were transferred at the same
time as sporozoite immunization (Figs. 2A Left and 3A). The
number of activated cells decreased by 10–20% when transfer
was performed 8 h later and was further reduced by 60 and
85% when the Tg cells were transferred 24 and 48 h after
immunization, respectively. CD8 T cells transferred 96 h after
immunization or later (data not shown) showed negligible
activation levels, comparable to control-immunized mice that
did not receive Tg cells. Importantly, the same results were
obtained when the magnitude of the CD8 T cell response was
evaluated by flow cytometry by using SYVPSAEQI-specific
tetramers (Fig. 2B). We also assessed the response of T cells
isolated from the liver (30), where sporozoites develop and
differentiate after infection and found that the kinetics of
activation of CD8 T cells isolated from the liver is similar to
that observed in the spleen (Fig. 2A Right).
Because activatedmemory CD8 T cells may have a higher
antigen-activation threshold (31–34) and therefore could display
different kinetics of antigen-driven activation, we performed iden-
tical adoptive transfer experiments by using activatedmemory
cells. These activatedmemory Tg CD8 T cells were obtained
from mice that previously received naı¨ve Tg cells and were immu-
nized with a recVAC (4, 19). In these experiments, we observed that
the kinetics of activation and expansion of the transferred activat-
edmemory CD8 T cells exposed to parasite antigen were similar
to those observed for naı¨ve cells, i.e., no expansion of the CD8 T
cell response is observed when T cells are transferred 96 h after
immunization. (Fig. 2C). It is noteworthy that when ELISPOT was
performed 16 days after transferring either activatedmemory or
naı¨ve Tg CD8 T cells instead of on day four, which is the peak of
the T cell response (15), the results were essentially the same;
CD8 T cells transferred 96 h after immunization were not
activated (data not shown). These observations indicate that a
low-level slowly developing T cell activation that is driven by
persisting antigen does not occur.
Whereas these results suggest that functional antigen presen-
tation occurs over a short period, they also raised the possibility
that a suppressive adaptive immune response induced immedi-
ately after sporozoite immunization could be responsible for the
lack of activation of CD8 T cells transferred 96 h after
immunization. This possibility was evaluated in experiments
using RAG2/ mice that lack both B and T cells (35). Along
with the transfer of Tg CD8 T cells at different hours after
sporozoite immunization, we also reconstituted these mice with
splenic CD4 T cells, which are critical for the induction of the
CD8 T cell response (16). Consistent with the previous results,
maximum activation of the naı¨ve Tg CD8 T cells was observed
when they were transferred at the same time of immunization,
whereas no expansion appeared to occur when the cells were
transferred after 96 h (Fig. 2D).
Parasite Viability or Route of Immunization Does Not Modify the
Parameters of Antigen-Driven T Cell Activation. The preceding
immunization experiments performed with radiation-attenuated
sporozoites injected intravenously directly address the T cell
Fig. 1. Persistence of the CD8 T cell response after a single immunization
with sporozoites. Normal mice received transgenic (Tg) CD8T cells; 24 h later,
they were immunized (}) i.v. with 5 104 attenuated sporozoites or were not
immunized (). The frequencies of epitope-specific CD8 T cells in the spleen
(Upper) and the liver (Lower) were determined by ELISPOT. Results represent
one of two similar experiments expressed as mean values  SD.
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response that occurs using the ‘‘gold standard’’ vaccine protocol
known to induce protective immunity against malaria. However,
this immunization condition may not represent the development
of the immune response under normal conditions of transmis-
sion. Indeed, whereas live and attenuated sporozoites are both
capable of invading hepatocytes, attenuated sporozoites undergo
only limited intracellular transformations, which could limit the
pool of antigen available for presentation to CD8 T cells.
Therefore, we tested the immunogenicity of live sporozoites to
determine whether parasite viability affects the antigen-driven T
Fig. 2. Short-term antigen presentation defines the magnitude of the CD8 T cell response. (A) Normal mice were immunized i.v. with 3  104 attenuated
sporozoites, and at different times postimmunization (8, 24, 48, 96 h), they received naı¨ve Tg CD8 T cells. The number and activation status of the Tg CD8
T cells in spleens (Left) and livers (Right) for each experimental group were assessed by ELISPOT 4 days after transfer of Tg cells. As controls for full activation,
mice received Tg cells at the time of immunization (0 h) and were analyzed 4 days later. Mice that were immunized but did not receive Tg cells (no Tg) served
as controls for the endogenous CD8 T cell response. (B) Spleen cells from A were stained with anti-CD8 antibodies and SYVPSAEQI tetramers. Plots were gated
on lymphocytes, and the number in the upper right corner represents the frequency of CD8 tetramer cells in the total CD8population. (C) Similar to A except
that mice received day 8 activatedmemory Tg CD8 T cells. Mice that received activatedmemory Tg cells but were not immunized (no spz) served as controls.
The activation of the Tg CD8T cells in the spleen was measured by ELISPOT 4 days after transfer. (D) Similar to A except that RAG2/mice were used. Immunized
mice received both naı¨ve Tg CD8 T cells and naı¨ve spleen lymphocytes at indicated times. The activation of the Tg CD8 T cells in the spleen was measured by
ELISPOT 4 days after transfer. Results in A–D represent one of two to three similar experiments.
Fig. 3. Parasite viability or route of immunization does not modify the parameters of antigen presentation and T cell activation. Normal mice were immunized
with 3 104 attenuated sporozoites (A), 3 104 live sporozoites (B), or four bites of irradiated infected mosquitoes (C). Naı¨ve Tg CD8 T cells were transferred
at indicated times after immunization, and the activation of the Tg CD8 T cells in the spleen was measured by ELISPOT 4 days after transfer. Mice that did not
receive Tg CD8 T cells (no Tg) served as control for the endogenous CD8 T cell response. Results in A–C represent one of two similar experiments and are
expressed as the relative number of CD8 T cells compared with 0 h (100%) to facilitate comparison.









cell activation. For this purpose, Tg cells were transferred into
mice at different time points after immunization with live
sporozoites, and their activation and expansion were assessed by
ELISPOT 4 days later, at a time when mice already display
incipient parasitemia. We found that mice immunized with live
parasites display a pattern of antigen presentation and T cell
activation identical to that observed in experiments using atten-
uated sporozoites (Fig. 3 A and B).
As the natural route of sporozoite infection is through mosquito
bites that inject parasites into the host skin, we also performed
experiments to evaluate the kinetics of antigen-driven activation of
CD8T cells when sporozoites are injected by mosquito bites. Mice
were exposed to the bites of four P. yoelii-infected irradiated
mosquitoes and received Tg CD8 T cells at different time points
after immunization. On the basis of the data available from the
literature and our recent work, we estimate that a single mosquito
bite injects 32–95 sporozoites (17, 18). Four days after T cell
transfer, the activation status of the Tg cells was assessed by
ELISPOT. Maximum numbers of activated cells were observed
when the Tg cells were transferred immediately before the exposure
of mice to mosquito bites (Fig. 3C). Again, transfer of Tg cells 96 h
later resulted in negligible levels of activation comparable to control
mice that did not receive Tg cells but were exposed to mosquito
bites. The results obtained in the preceding experiments strongly
indicate that nearly all functional antigen presentation to CD8 T
cells was of short duration and occurred within the first hours after
immunization.
Treatment with the Antimalaria Drug Primaquine and Development of
the CD8 T Cell Response. Previous studies have reported that
treatment of immunized mice with the antimalaria drug prima-
quine reduced the immunity induced after immunization with
sporozoites, and it was suggested that this drug could somehow
interfere with antigen presentation to CD8 T cells (20).
Therefore, we performed experiments to determine whether the
induction of CD8 T cells is affected in mice previously
receiving Tg cells and treated with primaquine at different times
before and after immunization (2, 8, 24, 48, 96 h). The
activation status of the Tg cells was assessed by ELISPOT 16 days
after immunization, and the results showed that CD8 T cell
responses were similar (Fig. 4). However, a small decrease in the
number of CD8 T cells could be observed in the group of mice
treated with primaquine at2 and 8 h. It is unclear whether this
marginal reduction is related to the antiparasite effect of this
drug or to the toxic effect on T cells described in previous studies
(36). Nevertheless, our results clearly indicate that primaquine
does not have a major effect on the induction and development
of the CD8 T cell response.
The Magnitude of the CD8 T Cell Response Is Determined by the Size
of the Priming Dose and Not by the Length of Time of Antigen
Presentation. Initially, we determined that large increases in the
magnitude of this CD8 T cell response could be easily induced
by increasing the amount of antigen used for immunization, i.e.,
the number of injected parasites (Fig. 5A). Our findings indi-
cating a short-term in vivo antigen presentation raised the
intriguing possibility that an enhanced CD8 T cell response
could be obtained not only by increasing the antigen dose but
also by artificially prolonging the length of the time of antigen
presentation, by performing repeated daily immunizations.
Therefore, we compared the CD8 T cell response of mice that
received Tg cells and were immunized with a single dose of 10
104 parasites, four doses of 2.5  104 parasites administered in
four consecutive days (total  10  104), or a single dose 2.5 
104 parasites. The activation and expansion of the CD8 T cells
were determined both by ELISPOT and FACS analysis 14 days
Fig. 4. Primaquine treatment and development of the CD8 T cell response.
Normal mice received Tg CD8 T cells and were immunized i.v. with 3  104
attenuated sporozoites. At indicated times before and after immunization,
mice were s.c. treated with 60 mgkg primaquine. The frequencies of epitope-
specific CD8 T cells in the spleens were measured by ELISPOT 16 days after
immunization. Results represent one of two similar experiments expressed as
mean values  SD. P value(untreated vs. treated, 2,8) 0.05 (t test).
Fig. 5. Dependence of the CD8 T cell response on priming dose and not on the length of time of antigen presentation. (A) Normal mice received and were
immunized i.v. with indicated amounts of attenuated sporozoites. The activation and expansion of the Tg CD8T cells in spleens (}) and livers () were measured
by ELISPOT 4 days after immunization. (B) Normal mice received Tg CD8 T cells and were immunized with the indicated doses of attenuated sporozoites.
The activation of the Tg CD8 T cells in the spleens and the livers were measured by ELISPOT 14 days after the primary immunization (Upper). Spleen cells
were stained with anti-CD8 antibodies and SYVPSAEQI tetramers, and plots were gated on lymphocytes; the number in the upper right corner represents the
frequency of CD8 tetramer cells in the total CD8population (Lower). Results in A and B represent one of two to three similar experiments (n3 micegroup).
P values(100K vs. 4  25K for both spleen and liver)0.05; P values(25K vs. 4  25K for both spleen and liver) not significant.
11822  www.pnas.orgcgidoi10.1073pnas.182189999 Hafalla et al.
after the first immunization. As expected, we observed a dose-
dependent difference in mice immunized with 2.5  104 and
10  104 sporozoites (Fig. 5B Upper). Remarkably, however, we
found that mice receiving four daily doses of 2.5  104 sporo-
zoites develop, in both the spleen and liver, a CD8 T cell
response comparable in magnitude to that observed in mice that
received a single dose of only 2.5  104 sporozoites. Similar
results were obtained when the response was evaluated by FACS
using SYVPSAEQI-specific tetramers (Fig. 5B Lower). The
inability to significantly increase the number of activated cells
after repeated antigen exposure suggests that a state of refrac-
toriness limits the magnitude of the immune response after the
single clonal burst induced by the primary immunization.
To determine whether the failure of the CD8 T cell response
to expand after repeated sporozoite immunization could also
occur under conditions resembling those found in malaria
endemic areas, we performed experiments in which we immu-
nized mice by repeated exposure to two bites of irradiated
infected mosquitoes. For this purpose, normal mice were im-
munized every 48 h such that different groups of mice received
a minimum of one immunization to a maximum of six. The
magnitude of the CD8 T cell response was determined by
ELISPOT 16 days after the first immunization. A clear CD8 T
cell response was observed in mice after receiving two immu-
nizations or four mosquito bites (Fig. 6). Remarkably, however,
we found no significant differences among mice receiving two,
three, four, or six immunizations. Again, these results clearly
indicate that once the primary T cell response becomes estab-
lished at a certain level, its magnitude could not be increased
despite additional exposure to antigen.
Discussion
The existence of persisting antigen and the possible role it may
have in the induction and maintenance of memory CD8 T cell
responses remains a controversial matter for most infectious
systems. The complexity of this issue is well illustrated by the
apparent contradictory results obtained in viral model systems,
in which the maintenance of the CD8 T cell response has been
described as either dependent on (23, 24, 29) or independent of
(25–28, 37) persisting antigen.
In this study, using Tg CD8 T cells specific for a defined
malaria antigen, we demonstrate that the length of time of in vivo
antigen presentation, as measured by the activation of these cells,
is relatively short but still generates a long-lasting antigen-
specific CD8 T cell response against malaria liver stages. A key
finding of our study is that the antigen-driven activation of
CD8 T cell precursors occurs within the first 48 h. Maximum
activation of CD8 T cells is observed within the first 8 h after
immunization, and no antigen-driven activation is observed 96 h
after immunization. Although it is not possible to demonstrate
the absence of antigen molecules 96 h after immunization, it is
nevertheless apparent that if they exist, they have no effect on
naı¨ve or activatedmemory CD8 T cells. Our results indicate
that this short-term functional in vivo antigen presentation
is sufficient to initiate the differentiation and proliferation
processes in T cells, which lasts for several days. This is consis-
tent with the notion that CD8 T cells undergo a predefined
developmental program of differentiation and clonal burst im-
mediately after antigenic stimulation (38–40).
The present study also revealed an intriguing phenomenon.
Although it is clear that the magnitude of the primary CD8 T
cell response closely correlates with the number of parasites used
for immunization, increasing the time of antigen presentation by
daily immunizations does not enhance the magnitude of this
response. These results suggest that a state of refractoriness
affects the CD8 T cell response immediately after priming,
which becomes unresponsive to further repeated immunizations.
The inability of CD8 T cells to expand further despite an
increased antigen exposure during the development of the primary
response is somehow reminiscent of what is observed in endemic
areas where very low frequencies of T cells against liver- stage
antigens are observed despite continued sporozoite inoculations
through the bites of malaria-infected mosquitoes (9, 10). Indeed, in
mice, we also demonstrated that repeated bites of infected mos-
quitoes failed to expand the number of activated cells once a
primary CD8T cell response was established. These results are of
interest as this mode of immunization not only mimics the manner
by which immunity to sporozoites is acquired in endemic areas, but
it is also known to induce sterile immunity against Plasmodium
falciparum in human volunteers (41–44).
The low frequencies of liver stage-specific CD8 T cells found
in endemic areas have been attributed to the existence of altered
peptide ligands brought about by polymorphisms in T cell epitopes
of parasite antigens (11, 12). It has been suggested that T cell
responses to liver stages can be negatively affected by antagonistic
peptides that could interfere with T cell priming and the survival of
memory T cells. This is definitely not the case for our findings,
because we are dealing with a parasite strain with no polymorphic
CD8 T cell epitope. It is also possible that immune effector
mechanisms, such as antibodies, can enhance the elimination of the
parasites from the circulation and thus interfere with antigen
processing and presentation. However, it is unlikely that such a
mechanism could explain the refractoriness we observed. Under
our immunization conditions, i.e., within the first 48 h, the protec-
tive immune response elicited after sporozoite immunization is
mostly mediated by T cells. In fact, depletion of CD8 T cells by
antibody treatment results in a significant abrogation of the inhi-
bition of liver stages (ref. 45 and data not shown).
It is intriguing that the inability of the CD8 T cells to
undergo further expansion contrasts with their ability to inhibit
parasite development, which is detectable as early as 24 h after
immunization and persists for several months (15). Therefore,
despite the relative ease in inducing primary T cell responses
even with minimal parasite exposure, there seems to be strong
regulatory mechanisms that inhibit the further expansion of
these T cells in response to additional antigen exposure. The
underlying mechanisms involved in this phenomenon of refrac-
toriness have yet to be fully elucidated.
The results presented in this study may have practical impli-
cations for the development of vaccines aimed at inducing high
numbers of long-lived memory T cells. They suggest that a
short-term antigen presentation rather than an extended antigen
presentation is more effective at generating maximal CD8 T
cell responses. Thus, the most efficient strategy for the induction
of CD8 T cell responses would rely on the delivery of a
maximal amount of antigen in a single dose. This would ensure
the induction of a single clonal burst involving the largest number
Fig. 6. A state of refractoriness limits the magnitude of the CD8 T cell
response despite repeated exposure to bites of infected mosquitoes. Normal
mice were immunized every 48 h with two bites of irradiated infected mos-
quitoes. The frequencies of epitope-specific CD8 T cells in the spleens were
measured by ELISPOT 16 days after the first immunization. Results represent
one of three similar experiments expressed as mean  SD.









of naı¨ve CD8 T cell precursors, which, following activation,
differentiate and become long-lived memory cells.
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